EcoDrugPlus

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSOJAG00000020856
Gene Symbol: NR1H4
1 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOJAG00000013765
Gene Symbol: NR3C1
1 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSOJAG00000022359
Gene Symbol: NR3C2
1 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSOJAG00000003016
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSOJAG00000011300
Gene Symbol: OPRL1
1 Cross references
188 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSOJAG00000013627
Gene Symbol: OPRD1
1 Cross references
191 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSOJAG00000017898
Gene Symbol: OPRD1B
1 Cross references
179 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSOJAG00000018634
Gene Symbol: OPRK1
1 Cross references
197 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSOJAG00000017355
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSOJAG00000001760
Gene Symbol: OXTR
1 Cross references
183 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSOJAG00000003873
Gene Symbol: OXTRA
1 Cross references
191 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSOJAG00000016724
Gene Symbol: PAK4
1 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).